InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (7 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
7
T+90 hit rate
73%
T+90 mean return
+6.2%
Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Swayze Eric, VP Exécutif. Insider active across 1 company, notably Ionis Pharmaceuticals INC. Aggregated, 24 reports have been logged. Split: 0 buy · 7 sells. Total volume traded: €683k. History available since 18 January 2022. The latest transaction was disclosed on 1 October 2025 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations24 total
10,602 sharesCommon StockSEC:0000874015-26-000211:0
14,142 shares@ US$53.7748.8% of flowCommon StockSEC:0000874015-25-000245
14,142 shares@ US$53.770.0050% mcap48.8% of flowCommon StockSEC:0000874015-25-000245:0
415 shares@ US$28.21150.4% of flowCommon StockSEC:0000874015-25-000103:0
3,714 shares0Common StockSEC:0000874015-25-000081:0
19,111 shares0Common StockSEC:0000874015-25-000065:0
1,194 shares@ US$37.9211.3% of flowCommon StockSEC:0000874015-24-000241:0
125 shares0Common StockSEC:0000874015-24-000229:0
1,940 shares@ US$49.56132.8% of flowCommon StockSEC:0000874015-24-000196:0
11 shares@ US$38.6410.0% of flowCommon StockSEC:0000874015-24-000221:0
605 shares@ US$34.4250.6% of flowCommon StockSEC:0000874015-24-000126:0
10,773 shares@ US$52.0016.2% of flowCommon StockSEC:0000874015-24-000110:0
17,069 shares0Common StockSEC:0000874015-24-000078:0
27,100 shares@ US$47.3436.1% of flowCommon StockSEC:0000874015-24-000006:0
125 shares0Common StockSEC:0000874015-23-000203:0
575 shares@ US$30.5150.5% of flowCommon StockSEC:0000874015-23-000115:0
3,715 shares0Common StockSEC:0000874015-23-000096:0
15,780 shares0Common StockSEC:0000874015-23-000069:0
460 shares@ US$44.550.6% of flowCommon StockSEC:0000874015-22-000157:0
1 shares@ US$45.200.0% of flowCommon StockSEC:0000874015-22-000149:0
378 shares@ US$44.150.0001% mcap1.2% of flowCommon StockSEC:0000874015-22-000101:0
621 shares@ US$28.3730.0001% mcap1.2% of flowCommon StockSEC:0000874015-22-000091:0
13,809 shares0Common StockSEC:0000874015-22-000050:0
13,809 shares0Common StockSEC:0000874015-22-000050
24 of 24 declarations
About Swayze Eric
Eric Swayze is the Executive Vice President of Research at IONIS Pharmaceuticals Inc. He leads the company's research efforts, focusing on the development of innovative new therapies. His leadership is essential in advancing research projects and improving patient outcomes.
